Chromosome 4q deletion syndrome (4q- syndrome) is a rare condition, with an estimated incidence of 1 in 100,000. Although variable, the clinical spectrum commonly includes craniofacial, developmental, digital, skeletal, and cardiac involvement. Data on the genotype-phenotype correlation within the 4q arm are limited. We present detailed clinical and genetic information by array CGH on 20 patients with 4q deletions. We identified a patient who has a ∼465 kb deletion (186,770,069-187,234,800, hg18 coordinates) in 4q35.1 with all clinical features for 4q deletion syndrome except for developmental delay, suggesting that this is a critical region for this condition and a specific gene responsible for orofacial clefts and congenital heart defects resides in this region. Since the patients with terminal deletions all had cleft palate, our results provide further evidence that a gene associated with clefts is located on the terminal segment of 4q. By comparing and contrasting our patients' genetic information and clinical features, we found significant genotype-phenotype correlations at a single gene level linking specific phenotypes to individual genes. Based on these data, we constructed a hypothetical partial phenotype-genotype map for chromosome 4q which includes BMP3, SEC31A, MAPK10, SPARCL1, DMP1, IBSP, PKD2, GRID2, PITX2, NEUROG2, ANK2, FGF2, HAND2, and DUX4 genes.
"The most frequently detected clinical manifestations include mild to moderate intellectual disability, learning disabilities and minor dysmorphic features [Cingoz et al., 2006]. There are only a few reports in which array-CGH analysis were conducted to delineate a genotype–phenotype correlation in chromosome 4 long arm deletions [Strehle et al., 2012]. To the best of our knowledge, no previous reports exist of cytogenetically detectable familial chromosome 4 long arm deletions which are not accompanied by any discernible phenotypic effects. "
"A number of patients have been reported with duplications and deletions of chromosome 4q33, the chromosomal region containing HAND2. Patients with both duplications and deletions have a high incidence of congenital heart defects including tetralogy of Fallot consistent with dosage sensitivity for this gene in human cardiogenesis but all duplications and deletions have affected multiple genes , . "
[Show abstract][Hide abstract] ABSTRACT: Objective
Rare variants in certain transcription factors involved in cardiac development cause Mendelian forms of congenital heart disease. The purpose of this study was to systematically assess the frequency of rare transcription factor variants in sporadic patients with the cardiac outflow tract malformation tetralogy of Fallot (TOF).
Methods and Results
We sequenced the coding, 5′UTR, and 3′UTR regions of twelve transcription factor genes implicated in cardiac outflow tract development (NKX2.5, GATA4, ISL1, TBX20, MEF2C, BOP/SMYD1, HAND2, FOXC1, FOXC2, FOXH, FOXA2 and TBX1) in 93 non-syndromic, non-Mendelian TOF cases. We also analysed Illumina Human 660W-Quad SNP Array data for copy number variants in these genes; none were detected. Four of the rare variants detected have previously been shown to affect transactivation in in vitro reporter assays: FOXC1 p.P297S, FOXC2 p.Q444R, FOXH1 p.S113T and TBX1 p.P43_G61del PPPPRYDPCAAAAPGAPGP. Two further rare variants, HAND2 p.A25_A26insAA and FOXC1 p.G378_G380delGGG, A488_491delAAAA, affected transactivation in in vitro reporter assays. Each of these six functionally significant variants was present in a single patient in the heterozygous state; each of the four for which parental samples were available were maternally inherited. Thus in the 93 TOF cases we identified six functionally significant mutations in the secondary heart field transcriptional network.
This study indicates that rare genetic variants in the secondary heart field transcriptional network with functional effects on protein function occur in 3–13% of patients with TOF. This is the first report of a functionally significant HAND2 mutation in a patient with congenital heart disease.
PLoS ONE 08/2014; 9(8):e95453. DOI:10.1371/journal.pone.0095453 · 3.23 Impact Factor
"Grossberger et al., 1999 GYPA/GYPB Encodes glucophorin A/B protein 4q31.21 Strehle et al., 2012 C4orf51/ ZNF827/ LSM6 Uncharacterized protein 4q31.22 Strehle et al., 2012 FG(A/B/G) Afibrinogenemia congenital, dysfibrinogenemia, hypodysfibrinogenemia, and thrombotic tendency 4q31.1q32.1 Neerman-Arbez et al., 2001; Vorjohann et al., 2010; Fabretto et al., 2012 NPY2R Stimulation of food intake, anxiolysis, modulation of circadian rhythm, pain transmission, control of pituitary hormone release 4q31.1q32.1 Rose et al., 1995 PDGFC Wound healing and fibrotic processes 4q31.1q32.1 Fabretto et al., 2012 GUCY1A3/ GUCY1B3 Regulate blood volume and Na + balance – main receptor for NO and nitrovasodilator drugs 4q31.1q32.1 Giuili et al., 1992; Zabel et al., 1998 TDO2 Relevance to alcoholism, depression, and Tourette syndrome 4q31.1q32.1 Comings et al., 1991; Comings, 2001 GRIA2 Amyotrophic lateral sclerosis 4q31.1q32.1 Ramanathan et al., 2004 GLRB Hyperekplexia 4q31.1q32.1 Ramanathan et al., 2004 ETFDH Type II glutaricacidemia 4q31.1q32.1 Fabretto et al., 2012 Downloaded by: "
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.